The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-06. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The Royal Air Force (RAF) provided surveillance and reconnaissance support, with an RAF surveillance plane tracked over the area where a Russian-linked tanker, Bella 1, was seized by US forces in January 2026. The UK provided one of its largest naval supply ships, the RFA Tideforce to support the US seizure of Bella 1 (renamed Marinera) in the North Atlantic, and UK military bases in the Atlantic were used by US planes and military assets involved in the operation.
The outer membrane of Gram-negative bacteria contains lipopolysaccharide, which acts as a barrier to vancomycin penetration. This barrier is why vancomycin is mainly used to treat infections caused by Gram-positive bacteria (except some nongonococcal species of Neisseria). The large hydrophilic molecule of vancomycin is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Under normal circumstances, this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents cell wall synthesis of the long polymers of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) that form the backbone strands of the bacterial cell wall, and prevents the backbone polymers from cross-linking with each other.
costmary, 1–66 grams sweet flag, 20 grams hypericum, 8 grams Natural gum, 8 grams sagapenum, 8 grams acacia juice, 8 grams Illyrian iris (probably I. germanica), 8 grams cardamom, 8 grams anise, 12 grams Gallic nard (Valeriana italica), 16 grams gentian root, 16 grams dried rose leaves, 16 grams poppy-tears (Papaver rhoeas, a wild poppy with low opiate content), 17 grams parsley, 17 grams cassia, 20–66 grams saxifrage, 20–66 grams darnel, 20–66 grams long pepper, 20–66 grams storax, 21 grams castoreum, 24 grams frankincense, 24 grams hypocistis juice, 24 grams myrrh, 24 grams opopanax, 24 grams malabathrum leaves, 24 grams flower of round rush, 24–66 grams turpentine-resin, 24–66 grams galbanum, 24–66 grams Cretan carrot seeds, 24–66 grams nard, 25 grams opobalsam, 25 grams shepherd's purse, 25 grams rhubarb root, 28 grams saffron, 29 grams ginger, 29 grams cinnamon, 29 grams The ingredients are then "pounded and taken up in honey. Against poisoning, a piece the size of an almond is given in wine. In other affections an amount corresponding in size to an Egyptian bean is sufficient." Of these ingredients, Illyrian iris, darnel, and rhubarb were not commonly found in other versions of the antidote. However, Celsus' formulation, written 100 years after the death of Mithridates, was one of the first published. Galen called the antidote "theriac" and presented versions by Aelius (used by Julius Caesar), Andromachus (physician to Nero), Antipater, Nicostratus, and Damocratis. The Andromachus formulation closely resembles that of Celsus.
The way a drug product is designed and manufactured Its physical and chemical properties Other ingredients it contains The physiologic characteristics of the person taking the drug How the drug is stored
=== February === 2 February Scientists report a possible way of solving the three-body problem; a notable problem of particular importance to physics and classical mechanics. Apple releases the Vision Pro as a virtual reality tool with visionOS. 5 February The proposed name Zoozve for Venus' quasi-moon 2002 VE is approved and announced by the International Astronomical Union's Working Group Small Bodies Nomenclature (WGSBN). A study based on 300-years-long temperature records preserved in Caribbean sclerosponge carbonate skeletons shows industrial-era warming already began in the mid-1860s and that by 2020, global warming was already 1.7±0.1 °C above pre-industrial levels. However, their reference period is not used by the IPCC and the 1.5 °C climate goal and the study's authors suggest their results show a better baseline. A study reports high life satisfaction in people with low incomes among small-scale societies outside mainstream societies, in contrast with conclusions of a 2023 adversarial collaboration. 6 February Scientists report a new species of mussel named Vadumodiolus teredinicola. Biologists report a new species of jellyfish named Santjordia pagesi. 7 February Reported science studies suggest that cosmic dust particles may have spread, in a process termed panspermia, life to Earth and elsewhere in the Universe. A battery based on calcium, able to charge and discharge fully 700 times at room temperature, is presented. It is described as a potential alternative to lithium, being 2,500 times more abundant on Earth.
Sources: en.wikipedia.org
3,4-Ethylenedioxythiophene (EDOT) is an organosulfur compound with the formula C2H4O2C4H2S. The molecule consists of thiophene, substituted at the 3 and 4 positions with an ethylene glycolyl unit. It is a colorless viscous liquid. EDOT is the precursor to the polymer PEDOT, which is found in electrochromic displays, photovoltaics, electroluminescent displays, printed wiring, and sensors.
The following week Admiral Alvin Holsey was denied a similar request to Antigua and Barbuda. The Grenadian government—working with CARICOM—later stated that a decision would be deferred, and in November Mitchell said that there was a non-disclosed deadline for approval of the radar station. In December 2025, Argentina asked the International Criminal Court (ICC) to activate an arrest warrant against Maduro, to which the Venezuelan government responded by accusing Argentina of "presenting itself as a false human rights defender", citing Argentina's support of Israel at the ICC. Chilean President-elect José Antonio Kast said during a visit to Argentina and meeting with Milei that he "supports any situation that ends a dictatorship" and that an intervention in Venezuela "would solve a gigantic problem for us and all of Latin America, for all of South America".
the number of molecules, etc. in a given amount of material is a fixed dimensionless quantity that can be expressed simply as a number, not requiring a distinct base unit; the SI thermodynamic mole is irrelevant to analytical chemistry and could cause avoidable costs to advanced economies the mole is not a true metric (i.e. measuring) unit, rather it is a parametric unit, and amount of substance is a parametric base quantity the SI defines numbers of entities as quantities of dimension one, and thus ignores the ontological distinction between entities and units of continuous quantities the mole is often used interchangeably and inconsistently in online sources to refer to both a unit and a quantity without appropriate use of amount of substance causing confusion for novice chemistry students.
=== Regulatory status === This medication first reached market in 1973. It is approved in 21 countries worldwide, which does not include its home country of Denmark. It was taken off the approved list in India in 2014, citing a lack of required information such as mandatory clinical trial results in its 1998 approval decision. It is approved in China.
There is much research currently underway looking at ways to protect the nerve (neuroprotection) or even regenerate new fibers within the optic nerve. So far there is no evidence in human studies that the so-called neuroprotectors have any beneficial effect in NAION. However, there is a new current clinical trial for the treatment of NAION in the United States with plans to include sites in India, Israel, Germany and Australia (see NORDICclinicaltrials.com and https://clinicaltrials.gov/). This trial will test the use of a synthetic siRNA that blocks caspase 2, an important enzyme in the apoptosis cycle. In addition to such research, patents have been applied for by Pfizer, The University of Southern California, Otsuka Pharmaceutical and other individual inventors for innovations related to the treatment of anterior ischemic optic neuropathy. In recent years, pentoxifylline has emerged as a potential treatment option for NAION and other diseases involving ocular ischemia. Pentoxifylline has been shown to reduce erythrocyte rigidity, resulting in decreased blood viscosity and increased flow velocity. Animal studies have demonstrated that pentoxifylline can inhibit TNF and, in turn, prevent retinal ganglion cell death and axonal degeneration associated with optic neuropathy in a dose-dependent manner.
Sources: en.wikipedia.org
Multituberculates (named for the multiple tubercles on their "molars") are often called the "rodents of the Mesozoic", due to their appearances, traits and attributes. In general, marsupial cuscuses, brushtail possums, and their close relatives (Phalangeridae), are more terrestrial than other members of the suborder Phalangeriformes, and resemble terrestrial primates in some respects, especially lemurs of Madagascar, which are prosimians. Both the placental superorder Euarchontoglires and diprotodont marsupials are documented to possess a vermiform appendix. Thoatherium had a single hoof similar to one of an horse and was even described to a "pseudo-horse".
== History == The party was established in 1919 by a merger of the Evolutionist Party and the Republican Union. The new party emerged as the largest in the 1921 elections, winning 79 of the 163 seats in the House of Representatives and 32 of the 71 seats in the Senate. However, it was beaten by the Democratic Party in the 1922 elections. In 1923 the party merged with the Reconstitution Party and the National Republican Party to form the Nationalist Republican Party.
By 12 January 2020, five genomes of SARS‑CoV‑2 had been isolated from Wuhan and reported by the Chinese Center for Disease Control and Prevention (CCDC) and other institutions; the number of genomes increased to 42 by 30 January 2020. A phylogenetic analysis of those samples showed they were "highly related with at most seven mutations relative to a common ancestor", implying that the first human infection occurred in November or December 2019. Examination of the topology of the phylogenetic tree at the start of the pandemic also found high similarities between human isolates. As of 21 August 2021, 3,422 SARS‑CoV‑2 genomes, belonging to 19 strains, sampled on all continents except Antarctica were publicly available. On 11 February 2020, the International Committee on Taxonomy of Viruses announced that according to existing rules that compute hierarchical relationships among coronaviruses based on five conserved sequences of nucleic acids, the differences between what was then called 2019-nCoV and the virus from the 2003 SARS outbreak were insufficient to make them separate viral species. Therefore, they identified 2019-nCoV as a virus of severe acute respiratory syndrome–related coronavirus. In July 2020, scientists reported that a more infectious SARS‑CoV‑2 variant with spike protein variant G614 has replaced D614 as the dominant form in the pandemic. Coronavirus genomes and subgenomes encode six open reading frames (ORFs). In October 2020, researchers discovered a possible overlapping gene named ORF3d, in the SARS‑CoV‑2 genome.
== Physiology and biochemistry == Streptococcus pneumoniae is one of the mostly highly studied bacterial species containing CSP, though other genus and species also utilize the hormone-like protein. Variations in structure, receptor specificity, and codon sequence occur even between different strains of the same species. However, homology between CSP's retain a single negatively charged N-terminus, an arginine residue in position three (C3), and a positively charged C-terminus. Signal-receptor specificity is demonstrated in Streptococcal species through the relationship between CSP1 and CSP2 signals, and the receptors ComD1 and ComD2. Variations of receptor specificity and composition can be estimated based on nuclear magnetic resonance (NMR) spectroscopy analysis. Alterations in the structure of CSP signals, such as CSP1 and CSP2, are shown to inhibit the cellular response to these peptides, often resulting in reduced biofilm production. Replacement of the first glutamate residue in CSP1 inhibits receptor activation of competency genes, and hydrophobic regions on the CSP1 molecule play key roles in effective ComD1 and Com2 binding. Interspecies interactions between biofilm producing organisms induce the release of chemical signals that inhibit binding or receptor activation in competence stimulating processes. Initiation of DNA transformation begins as a threshold concentration of CSP is met within a bacterial cell. Cellular density is proportional to CSP concentration.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.